Dr. Kluger on a Phase I Trial of Concurrent Nivolumab and Ipilimumab

Harriet Kluger, MD
Published: Sunday, Sep 28, 2014

Harriet Kluger, MD, associate professor of medicine, Yale Cancer Center, discusses the results from a phase I trial of nivolumab and ipilimumab for the treatment of patients with advanced melanoma.

The overall response rate of patients on the trial was over 40%, Kluger says, while one- and two- year overall survival rates were 85% and 79%, respectively. This type of survival has never been seen before in metastatic melanoma.

Kluger notes that many patients had a poor prognosis prior to the trial – many had elevated LDH and 53% of patients were M1c.

<<< View more from the 2014 ESMO Congress

Harriet Kluger, MD, associate professor of medicine, Yale Cancer Center, discusses the results from a phase I trial of nivolumab and ipilimumab for the treatment of patients with advanced melanoma.

The overall response rate of patients on the trial was over 40%, Kluger says, while one- and two- year overall survival rates were 85% and 79%, respectively. This type of survival has never been seen before in metastatic melanoma.

Kluger notes that many patients had a poor prognosis prior to the trial – many had elevated LDH and 53% of patients were M1c.

<<< View more from the 2014 ESMO Congress




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Publication Bottom Border
Border Publication
x